<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of uncomplicated gonorrhea (&lt;i&gt;Neisseria gonorrhoeae&amp;nbsp;&lt;/i&gt;infection) in adults and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of uncomplicated gonorrhea (<i>Neisseria gonorrhoeae </i>infection) in adults and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arlene C Seña, MD, MPH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Myron S Cohen, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeanne Marrazzo, MD, MPH, FACP, FIDSA</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 20, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H7888990"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Gonococcal infections, including urethritis, cervicitis, epididymitis, and proctitis, are a significant cause of morbidity among sexually active men and women. The treatment of these sexually transmitted infections (STIs) has evolved over the years, mainly due to the emergence of antibiotic resistance.</p><p>This topic will address the treatment of these gonococcal infections, with a focus on urogenital infections. The discussion in this topic is largely consistent with the United States Centers for Disease Control and Prevention (CDC) recommendations on treatment of STIs, which were updated in 2021 [<a href="#rid1">1</a>]. </p><p>The clinical manifestations and diagnosis of gonorrhea are discussed elsewhere. The treatment of complicated infections, such as disseminated gonococcal infection and pelvic inflammatory disease, is also found elsewhere.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7587.html" rel="external">"Epidemiology and pathogenesis of <i>Neisseria gonorrhoeae</i> infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15893.html" rel="external">"Clinical manifestations and diagnosis of <i>Neisseria gonorrhoeae </i>infection in adults and adolescents"</a> and  <a class="medical medical_review" href="/d/html/15867.html" rel="external">"Cutaneous manifestations of gonorrhea"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7603.html" rel="external">"Disseminated gonococcal infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents"</a>.)</p><p></p><p>Prevention of gonorrhea and other STIs is also discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7595.html" rel="external">"Prevention of sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H7888997"><span class="h1">GENERAL BACKGROUND</span></p><p class="headingAnchor" id="H1898397070"><span class="h2">Definition of uncomplicated infection</span><span class="headingEndMark"> — </span>Urogenital, anogenital, pharyngeal, and ocular gonococcal infections that are not associated with bacteremic or ascending spread of the pathogen to other organs are considered uncomplicated.</p><p>In contrast, disseminated gonococcal infection and pelvic inflammatory disease are complicated infections. Treatment of these is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7603.html" rel="external">"Disseminated gonococcal infection", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents", section on 'Antibiotic selection'</a>.)</p><p class="headingAnchor" id="H1115797"><span class="h2">Therapeutic principles</span><span class="headingEndMark"> — </span>Antimicrobial treatment is required for all patients diagnosed with gonorrhea. It is a highly transmissible infection that can result in serious sequelae if untreated, even in asymptomatic individuals. The role of treatment is to resolve symptoms if present, prevent complications of infection, and decrease transmission to others.</p><p>It is desirable for a therapeutic gonococcal regimen to:</p><p class="bulletIndent1"><span class="glyph">●</span>Be highly effective at all anatomic sites of infection</p><p class="bulletIndent1"><span class="glyph">●</span>Be well tolerated (particularly in patients with recurrent infections)</p><p class="bulletIndent1"><span class="glyph">●</span>Offer the feasibility of single-dose therapy at the point of care</p><p></p><p>Therapeutic regimens should have efficacy rates of greater than 95 percent because treatment failure has significant public health implications related to ongoing transmission of infection [<a href="#rid2">2,3</a>]. Single-dose therapy decreases the reliance on patient adherence; nonadherence can negatively affect eradication rates and increase the risk of drug resistance. Because of progressive development of drug resistance to various classes of antibiotics, at present, only one drug, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, meets these strict treatment efficacy goals with single-dose therapy, few adverse effects, and relatively low rates of drug resistance [<a href="#rid4">4</a>]. (See <a class="local">'Antibiotic resistance'</a> below and <a class="local">'Initial treatment of urogenital infection'</a> below.) </p><p class="headingAnchor" id="H1115804"><span class="h2">Copathogens</span><span class="headingEndMark"> — </span>The selection of antibiotics for the treatment of gonorrhea must also consider the possibility of copathogens, such as <em>Chlamydia trachomatis </em>and<em> Mycoplasma genitalium</em>, which can cause cervicitis in women and urethritis in men [<a href="#rid5">5-7</a>]. Some epidemiologic surveys have shown a coinfection rate for <em>C. trachomatis</em> of up to 46 percent among men and women with gonorrhea [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection"</a> and  <a class="medical medical_review" href="/d/html/89490.html" rel="external">"Epidemiology of <i>Chlamydia trachomatis</i> infections"</a> and  <a class="medical medical_review" href="/d/html/83202.html" rel="external">"<i>Mycoplasma genitalium</i> infection"</a>.) </p><p class="headingAnchor" id="H7889004"><span class="h1">ANTIBIOTIC RESISTANCE</span><span class="headingEndMark"> — </span>The era of <em>N. gonorrhoeae</em> antibiotic resistance began in the 1940s with the emergence of sulfonamide resistance. Subsequently, gonococcal infections were treated with penicillins, but by 1989, &gt;5 percent of cases of gonorrhea were caused by strains that produced a plasmid-mediated beta-lactamase and &gt;17 percent were associated with chromosomally-mediated resistance [<a href="#rid2">2</a>]. <em>N. gonorrhoeae</em> has uniformly developed increasing minimum inhibitory concentrations (ie, decreasing susceptibility) to antibiotics employed for treatment, followed by frank resistance, thus progressively reducing available therapeutic options [<a href="#rid8">8</a>].</p><p>Most of the data on gonococcal drug resistance is inferred through in vitro susceptibility data and epidemiologic surveys, rather than through clinical trials demonstrating increased treatment failure rates. In the United States, trends in drug resistance among males with urethral gonorrhea at sentinel sites throughout the country have been monitored by the Centers for Disease Control and Prevention (CDC)-sponsored Gonococcal Isolate Surveillance Project (GISP), which was created in 1986 [<a href="#rid2">2</a>]. Similar programs have been collecting data on <em>N. gonorrhoeae</em> antimicrobial resistance in other regions of the world [<a href="#rid9">9-11</a>]. Such surveillance programs have demonstrated increased resistance worldwide to multiple classes of antibiotics, including penicillins, tetracyclines, macrolides, and fluoroquinolones, with documented cross-resistance between two or more classes [<a href="#rid12">12,13</a>]. An especially alarming trend in <em>N. gonorrhoeae</em> drug resistance has been the progressive decrease in susceptibility to the cephalosporins and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> [<a href="#rid14">14</a>]. (See <a class="local">'Cephalosporins'</a> below.) </p><p>The emerging threat of antimicrobial-resistant gonorrhea is more evident among men who have sex with men (MSM) than among men who have sex exclusively with women (MSW). Surveillance data from GISP which included more than 34,000 episodes of symptomatic gonorrhea found that isolates from MSM were significantly more likely to demonstrate antimicrobial resistance to all the antibiotic classes noted above, including cephalosporins, than isolates from MSW [<a href="#rid15">15</a>]. </p><p>In 2023, the first isolates of multidrug-resistant (MDR) <em>N. gonorrhoeae</em> with reduced susceptibility to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a>, and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> and resistance to <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a>, penicillin, and <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> were reported in the United States [<a href="#rid16">16</a>]. The MDR <em>N. gonorrhoeae</em> strain was previously identified in the United Kingdom [<a href="#rid17">17</a>] and the Asia-Pacific region. Although ceftriaxone was effective for treatment, the isolates were confirmed to have the presence of a mosaic penA60 allele conferring reduced ceftriaxone susceptibility [<a href="#rid18">18</a>]. (See <a class="local">'Ceftriaxone'</a> below.)</p><p>In the setting of these trends, there has been renewed interest in drugs from other antibiotic classes, such as the carbapenems (eg, <a class="drug drug_general" data-topicid="8675" href="/d/drug information/8675.html" rel="external">ertapenem</a>), as potentially effective agents for individualized therapy, as dictated by resistance data [<a href="#rid14">14,19-22</a>]. In addition, new drugs are in development. (See <a class="local">'Monitoring for and managing treatment failure'</a> below and <a class="local">'Investigational strategies'</a> below.)</p><p class="headingAnchor" id="H77502526"><span class="h2">Cephalosporins</span><span class="headingEndMark"> — </span>The rising rates of gonococcal resistance to non-cephalosporin classes of antimicrobial agents led to the use of cephalosporins, particularly intramuscular injections of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> and oral <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> [<a href="#rid23">23</a>]. However, trends in increasing mean minimum inhibitory concentrations (MICs) of <em>N. gonorrhoeae</em> for both agents, indicating decreasing susceptibility, have been reported worldwide and have led to changes in the recommendations for use of these agents. (See <a class="local">'Preferred regimen'</a> below.)</p><p>The Clinical and Laboratory Standards Institute (CLSI) has not defined MIC criteria for resistance of <em>N. gonorrhoeae</em> to cephalosporins but considers MIC ≥0.5 mcg/mL to reflect decreasing susceptibility. However, surveillance uses lower breakpoints (for example, ≥0.125 mcg/mL for <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> and ≥0.25 mcg/mL for <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a>) to indicate decreasing susceptibility in order to better detect trends in emerging resistance [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H365932"><span class="h3">Cefixime</span><span class="headingEndMark"> — </span>Surveillance of <em>N. gonorrhoeae</em> samples in the United States demonstrates that the percentage of isolates with elevated <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> MICs (≥0.25 mcg/mL) increased from 0.1 percent in 2006 to 1.4 percent in 2010, started to decline in 2015, and was 0.3 percent in 2020 [<a href="#rid24">24</a>]. Among 23 European countries reporting on cefixime susceptibility in the World Health Organization Gonococcal Surveillance Programme (GASP), four countries (Belgium, Denmark, Greece, and Norway) reported resistance rates ≥5 percent [<a href="#rid25">25</a>]. Although no confirmed treatment failures with cefixime have been reported in the United States as of 2020, such failures have been reported in Canada, Europe, and Japan [<a href="#rid26">26-29</a>]. Furthermore, in a retrospective study of patients treated for culture-confirmed <em>N. gonorrhoeae</em> infection with a single oral dose of cefixime 400 mg at a Canadian clinic, 13 of 133 patients who returned for a test of cure were again culture positive, and nine (6.8 percent) were considered treatment failures [<a href="#rid30">30</a>]. With regards to location of infection, clinical failure occurred in 4 of 76 urethral, 2 of 7 pharyngeal, and 3 of 39 rectal infections (5.3, 28.6, and 7.7 percent, respectively). Although the possibility that some of these cases represented reinfection instead of treatment failure cannot be definitively excluded, these data highlight the increasing concern of the inadequacy of cefixime for gonococcal infections.</p><p>In light of domestic MIC trends and international treatment failures, <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> is not a preferred agent for the treatment of gonorrhea [<a href="#rid1">1</a>]. (See <a class="local">'Other cephalosporins'</a> below.)</p><p class="headingAnchor" id="H291944443"><span class="h3">Ceftriaxone</span><span class="headingEndMark"> — </span>Decreasing susceptibility and resistance of gonorrhea to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> have emerged as a global problem. In 2011, the first <em>N. gonorrhoeae</em> strain with high-level resistance to ceftriaxone (MIC 2 to 4 mcg/mL) was isolated from the pharynx of a sex worker in Japan [<a href="#rid31">31,32</a>]. This was followed by a report from France of a different ceftriaxone-resistant strain isolated from the urethra of an MSM who had earlier failed treatment with <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> [<a href="#rid33">33</a>]. Ceftriaxone-resistant isolates have subsequently been identified in other countries, including the United States and United Kingdom [<a href="#rid18">18,34</a>], and ceftriaxone treatment failure has been documented in locations such as Australia and Europe [<a href="#rid35">35-37</a>]. (See <a class="local">'Monitoring for and managing treatment failure'</a> below.)</p><p>There has also been a progressive evolution over time toward higher MICs for <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> globally, as reflected by resistance patterns in isolates reported to surveillance programs in the United States, Canada, Latin America, Europe, Australia, and Asia [<a href="#rid9">9,10,38-43</a>]. Between 2016 and 2020 in the United States, the proportion of reported gonococcal isolates with decreased susceptibility to ceftriaxone (MIC ≥0.125 mcg/mL) has fluctuated between 0.1 and 0.3 percent [<a href="#rid24">24</a>]. Rates of decreased susceptibility to ceftriaxone exceed 5 percent in many countries/regions throughout Asia, including Japan, South Korea, Hong Kong, India, and Indonesia [<a href="#rid44">44</a>].</p><p>These developments highlight the pressing need for improving control of the spread of drug resistance in <em>N. gonorrhoeae</em> and clinically investigating other viable therapeutic options [<a href="#rid8">8,45,46</a>]. Nevertheless, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> remains a highly reliable treatment, especially at higher doses. (See <a class="local">'"High" dose intramuscular (IM) ceftriaxone'</a> below.)</p><p class="headingAnchor" id="H77502541"><span class="h2">Azithromycin</span><span class="headingEndMark"> — </span>Drug resistance to macrolides has been increasing significantly worldwide, according to gonococcal surveillance data. In the United States, data from the GISP demonstrate increasing MICs for <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> since surveillance for the drug's activity against <em>N. gonorrhoeae</em> began in 1992, and elevated MICs have been reported in all geographic regions [<a href="#rid47">47,48</a>]. In 2020, 5.8 percent of isolates had an azithromycin MIC ≥2 mcg/mL (indicating reduced susceptibility), an increase from 0.3 percent in 2011 and 3.6 in 2016 [<a href="#rid24">24</a>]. The risk of azithromycin resistance might be particularly high among MSM; in one study from an urban STI clinic, 93 percent of isolates with decreased susceptibility to azithromycin were from MSM, among the prevalence of azithromycin MIC ≥2 mcg/mL was 5 percent [<a href="#rid48">48</a>]. Very high-level resistance to azithromycin (MIC &gt;512 mcg/mL) has also been reported in the United States, first identified in Hawaii, and several such isolates have also demonstrated reduced susceptibility to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> [<a href="#rid49">49,50</a>]. </p><p>In Europe, the prevalence of decreased susceptibility to <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (MIC ≥1 mcg/mL) ranges from none (eg, in France and Iceland) to 23 and 33 percent in Greece and Cyprus, with a mean of 5.4 percent across 21 countries [<a href="#rid9">9</a>]. Azithromycin resistance is also common in Asia [<a href="#rid51">51-53</a>], where rates exceed 5 percent in Japan, Hong Kong, Mongolia, and Indonesia [<a href="#rid25">25</a>]. One laboratory study of gonococcal isolates in Hong Kong from 2005 to 2010 demonstrated that 30 percent of all gonococcal isolates were azithromycin resistant [<a href="#rid54">54</a>].</p><p>Decreased susceptibility to <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> has been associated with recent use of azithromycin (eg, for other STIs) [<a href="#rid55">55</a>]. </p><p>These findings emphasize the importance of ongoing drug resistance surveillance for all drugs commonly used in the treatment of gonorrhea and prompted reversal of the recommendations for dual <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> and <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> therapy for gonorrhea in the United States and other countries. (See <a class="local">'Preferred regimen'</a> below.)</p><p class="headingAnchor" id="H366617"><span class="h2">Tetracycline</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">Tetracycline</a> resistance has been reported in the range of 10 to 20 percent of gonococcal isolates in the United States and Europe [<a href="#rid47">47,56</a>]. Cross-resistance to <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> is presumed.</p><p class="headingAnchor" id="H366145"><span class="h2">Aminoglycosides</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spectinomycin </strong>– Resistance to spectinomycin has remained low in systematic surveillance reports from the United States, Europe, and Australia [<a href="#rid9">9,10,47</a>]. However, this agent is not available in the United States and is otherwise not widely used in other areas. When it was used more frequently as a single agent, resistance was more common. Among 99 United States military personnel treated for urethral gonorrhea in Korea (where spectinomycin monotherapy was the preferred regimen), 8.2 percent experienced treatment failure and 6.1 percent had laboratory confirmed high-level resistance to spectinomycin [<a href="#rid57">57</a>]. (See <a class="local">'Spectinomycin'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gentamicin</strong> – Although susceptibility breakpoints for <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> have not been defined for <em>N. gonorrhoeae</em>, the overall MICs are low across Europe [<a href="#rid9">9</a>]. In Malawi, gentamicin has been used with <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> as first-line syndromic treatment for urethritis for years [<a href="#rid58">58</a>]. However, in a more recent study of males with gonococcal urethritis in Malawi, 19.9 percent of <em>N. gonorrhoeae</em> isolates had elevated MICs to gentamicin; furthermore, MICs poorly predicted response to gentamicin, with gentamicin treatment failure observed with isolates that had low MICs [<a href="#rid59">59</a>]. Surveillance for gentamicin susceptibility is not being performed in the United States. The potential clinical use of gentamicin (in combination with <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>) is discussed elsewhere. (See <a class="local">'Azithromycin plus gentamicin or gemifloxacin'</a> below.)</p><p></p><p class="headingAnchor" id="H77502534"><span class="h2">Fluoroquinolones</span><span class="headingEndMark"> — </span>The prevalence of quinolone-resistant <em>N. gonorrhoeae</em> (QRNG) ranges from 10 to nearly 100 percent of isolates reported throughout the world, and these drugs are no longer recommended for the treatment of gonorrhea [<a href="#rid2">2,9,10</a>]. In several regions, such as the United States and Europe, the prevalence of quinolone resistance has decreased somewhat compared with previous years, likely reflecting decreased use of the drug [<a href="#rid9">9,47</a>]. However, resistance levels remain high elsewhere despite the avoidance of these drugs for treatment of gonorrhea and the resultant decrease in selection pressure. In vitro and animal studies suggest that certain quinolone resistance mutations also confer a fitness advantage, which could explain the persistence of resistance in the absence of selection pressure [<a href="#rid60">60,61</a>].</p><p>Several molecular tests that identify the gyrase A gene point mutation associated with fluoroquinolone resistance are under development and may allow reintroduction of fluoroquinolone therapy by allowing rapid identification of susceptible isolates. In one study of 106 patients identified as having a fluoroquinolone-susceptible <em>N. gonorrhoeae</em> infection based on one such test, a single-dose of <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> resulted in microbiologic cure at all anatomic sites among those who had sufficient follow-up; the molecular testing results correlated with in vitro susceptibility testing [<a href="#rid62">62</a>].</p><p class="headingAnchor" id="H1115841"><span class="h1">INITIAL TREATMENT OF UROGENITAL INFECTION</span><span class="headingEndMark"> — </span>The alarming rates of antibiotic resistance to <em>N. gonorrhoeae</em> reported worldwide has rendered the treatment of uncomplicated gonococcal infections more complex, with fewer treatment options, than in the past [<a href="#rid12">12,63,64</a>]. Due to rising rates of gonococcal resistance to other agents (sulfonamides, penicillins, tetracyclines, and fluoroquinolones), third-generation cephalosporins are considered first-line monotherapy [<a href="#rid1">1</a>]. Of these, <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is favored because drug resistance and treatment failure have been documented less frequently than with other cephalosporins, such as <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a>. </p><p class="headingAnchor" id="H278540"><span class="h2">Preferred regimen</span></p><p class="headingAnchor" id="H4033437991"><span class="h3">"High" dose intramuscular (IM) ceftriaxone</span><span class="headingEndMark"> — </span>Single-agent therapy with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is the preferred regimen for treatment of gonococcal infections. We agree with the following dose recommendations from the United States Centers for Disease Control and Prevention (CDC) for treatment of uncomplicated gonococcal infections [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For individuals who weigh &lt;150 kg – <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">Ceftriaxone</a> 500 mg IM in a single dose</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For individuals who weigh ≥150 kg – <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">Ceftriaxone</a> 1 g IM in a single dose</p><p></p><p>These doses of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> are higher than previously recommended due to concerns regarding rising gonococcal minimum inhibitory concentrations (MICs) worldwide. High doses of ceftriaxone are also recommended by other national guidelines; for example, 1 g as a single dose (IM or intravenously) is recommended by the British Association for Sexual Health and HIV (BASHH) in the United Kingdom [<a href="#rid65">65</a>], in China [<a href="#rid66">66,67</a>], and in Japan [<a href="#rid68">68,69</a>]. </p><p>Additionally, routine use of a second agent for treatment of gonococcal infections, which was included in previous CDC treatment guidelines, is no longer recommended. However, if chlamydial coinfection has not been excluded (eg, nucleic acid amplification testing [NAAT] at exposed sites has not been performed), presumptive treatment of chlamydia should be administered at the same time. (See <a class="local">'Presumptive treatment for chlamydia'</a> below.)</p><p><a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">Ceftriaxone</a> is highly effective against susceptible <em>N. gonorrhoeae</em>. Earlier studies had suggested that ceftriaxone dosed IM at either 125 mg or 250 mg resulted in microbiologic cure in 99 percent of uncomplicated urogenital and anorectal infections [<a href="#rid4">4,70</a>]. Ceftriaxone is also more effective than oral cephalosporins. In a meta-analysis of trials evaluating treatment of uncomplicated gonorrhea, higher cure rates were reported with ceftriaxone 250 mg than <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> 400 mg (odds ratio [OR] 1.77, 95% CI 1.11-2.8) with equivalent side effects [<a href="#rid70">70</a>]. </p><p>However, these doses (125 mg to 250 mg) are unlikely to be effective against isolates with higher MICs, which have increased in prevalence since those trials were performed. Pharmacokinetic and pharmacodynamic modeling and animal studies have demonstrated that a dose of at least 5 mg/kg of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is necessary to achieve levels higher than an MIC ≥0.125 mcg/mL (the threshold for decreased susceptibility to ceftriaxone) for a sufficient duration of time above the MIC [<a href="#rid38">38,71</a>]. Thus, the CDC has increased the recommended dose of ceftriaxone from 250 mg to 500 mg or 1 g in a single dose, depending on the patient's weight. Additionally, pharyngeal infection, which is often asymptomatic and may accompany infection at other sites, is more difficult to eradicate than urogenital or anorectal gonococcal infections and may serve as a reservoir of infection, possibly related to less predictable ceftriaxone levels in the pharynx [<a href="#rid72">72</a>]. This consideration was another reason for the increase in the recommended dose. (See <a class="local">'Pharyngeal infection'</a> below.)</p><p>Evaluation for cephalosporin resistance in patients with persistent or recurrent symptoms is essential to controlling the spread of drug resistance. Thus, all patients need to understand the importance of further evaluation if symptoms persist. (See <a class="local">'Monitoring for and managing treatment failure'</a> below.)</p><p>The current recommendations also reflect a departure from prior recommendations for dual therapy of gonorrhea with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> [<a href="#rid1">1</a>]. Dual therapy did not improve gonorrhea clearance rates [<a href="#rid73">73</a>] but had been theorized to reduce the risk of emergent resistance, based on evidence from other pathogens that demonstrated lower rates of resistance with the use of at least two agents that act upon different molecular targets. However, this was never demonstrated for <em>N. gonorrhoeae</em>, and in fact, treatment failure of a pharyngeal infection following dual therapy with subsequent decreased susceptibility to ceftriaxone and azithromycin has been reported [<a href="#rid74">74</a>]. Decreasing susceptibility to azithromycin in <em>N. gonorrhoeae</em> and other organisms is now thought to outweigh any theoretical benefit [<a href="#rid1">1,48</a>]. (See <a class="local">'Azithromycin'</a> above.)</p><p>Agents other than <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> are not appropriate as preferred regimens because of high rates of resistance. (See <a class="local">'Antibiotic resistance'</a> above.)</p><p>Clinical trials and novel therapeutics are urgently needed to identify the most appropriate treatment strategy for <em>N. gonorrhoeae</em> in the face of rising antimicrobial resistance. (See <a class="local">'Investigational strategies'</a> below.)</p><p class="headingAnchor" id="H3534059366"><span class="h3">Presumptive treatment for chlamydia</span><span class="headingEndMark"> — </span>If concurrent <em>C. trachomatis</em> infection has not been excluded with molecular testing, presumptive treatment for chlamydia should be given at the same time as treatment for <em>N. gonorrhoeae</em>. We agree with CDC recommendations to use <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> (100 mg orally twice daily for seven days) for presumptive treatment of chlamydia in nonpregnant individuals with gonococcal infection. (See  <a class="medical medical_review" href="/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection", section on 'Doxycycline as preferred agent'</a>.)</p><p><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> is an alternative to <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a> for treatment of chlamydia. Increasing rates of decreased azithromycin susceptibility among <em>N. gonorrhoeae</em> isolates have been reported [<a href="#rid75">75</a>], and azithromycin exposure has been associated with high azithromycin MICs in <em>N. gonorrhoeae</em> [<a href="#rid76">76</a>]. (See <a class="local">'Azithromycin'</a> above.)</p><p class="headingAnchor" id="H7889039"><span class="h2">Alternate regimens</span><span class="headingEndMark"> — </span>Alternate regimens should only be used if the preferred regimen is not available or precluded because of severe allergies or intolerance. If <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is not available, certain other cephalosporins can be used in its place. In the case of severe hypersensitivity reactions to cephalosporins, options include high-dose <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> with <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> or <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">gemifloxacin</a> and spectinomycin. However, both gemifloxacin and spectinomycin have limited or no availability in the United States, and these alternate regimens all have drawbacks that further limit their use, as discussed below.</p><p class="headingAnchor" id="H952811253"><span class="h3">Other cephalosporins</span><span class="headingEndMark"> — </span>For treatment of urogenital or anorectal gonococcal infection in situations where <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is not available, a different injectable cephalosporin (eg, ceftizoxime [500 mg IM], <a class="drug drug_general" data-topicid="9223" href="/d/drug information/9223.html" rel="external">cefoxitin</a> [2 g IM with <a class="drug drug_general" data-topicid="9812" href="/d/drug information/9812.html" rel="external">probenecid</a> 1 g orally], or <a class="drug drug_general" data-topicid="9221" href="/d/drug information/9221.html" rel="external">cefotaxime</a> [500 mg IM]) can be used; however, there is <strong>no</strong> advantage of any of these injectable cephalosporins over ceftriaxone, and their efficacy in pharyngeal infection is less certain. Additionally, availability of these agents may be limited (eg, injectable ceftizoxime and cefotaxime are not available in the United States). </p><p>If an injectable cephalosporin is not available, <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> is the only oral cephalosporin that can be used for gonococcal therapy. The recommended dose is 800 mg orally once, which is an increased dose compared with prior recommendations [<a href="#rid1">1</a>]. Cefixime has been shown to result in microbiologic cure in more than 96 percent of patients with uncomplicated urogenital or anorectal gonorrhea [<a href="#rid77">77,78</a>]. However, it is not as effective as <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> [<a href="#rid70">70</a>], and in particular, cefixime has been associated with high treatment failure rates for pharyngeal gonorrhea infection [<a href="#rid30">30,79</a>]. These studies had evaluated cefixime at a lower dose of 400 mg. An increased dose has been recommended to increase plasma levels of the drug in light of these findings and decreased susceptibility of <em>N. gonorrhoeae</em> to oral cephalosporins in the United States and throughout other parts of the world [<a href="#rid54">54,80,81</a>]. (See <a class="local">'Cephalosporins'</a> above.)</p><p>For any of these regimens, additional therapy for chlamydia is warranted if coinfection has not been ruled out. (See <a class="local">'Presumptive treatment for chlamydia'</a> above.)</p><p class="headingAnchor" id="H396126287"><span class="h3">Azithromycin plus gentamicin or gemifloxacin</span><span class="headingEndMark"> — </span>Some patients with beta-lactam allergies can still use a cephalosporin (see <a class="local">'Penicillin-allergic patients'</a> below). For patients with urogenital or anorectal gonococcal infection who have severe allergies that preclude cephalosporin use, we favor <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (240 mg IM once for individuals &gt;45 kg; 5 mg/kg IM once for individuals ≤45 kg) plus <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (2 g orally once). <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">Gemifloxacin</a> (320 mg orally once) plus azithromycin (2 g orally once) can also be used as an alternate regimen; however, the limited availability and cost of gemifloxacin can be prohibitive. In the United States, the CDC does not include the gemifloxacin combination as an alternative regimen because of these and antimicrobial stewardship concerns.</p><p>There are limited data regarding the efficacy of both alternative regimens for extragenital infections. Furthermore, adverse effects (eg, gastrointestinal [GI] side effects with the higher dose of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a>), other toxicities, and availability may limit their use. Azithromycin monotherapy for gonorrhea is <strong>not</strong> recommended. The primary reason for using a second agent with azithromycin is to prevent the emergence of azithromycin resistance, but this theoretical benefit has not been directly evaluated in studies. If one of these regimens is used, additional therapy for chlamydia is not necessary, even if it has not been ruled out.</p><p>Some evidence suggests that these regimens are highly effective for urogenital and anogenital infections. The combinations of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (2 g orally once) with either <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> or <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">gemifloxacin</a> were evaluated in a study of men and women who presented with suspected gonococcal urethritis or cervicitis to sexually transmitted infection (STI) clinics in the United States [<a href="#rid82">82</a>]. Approximately one-third of the participants were men who have sex with men (MSM). Among the patients with documented <em>N. gonorrhoeae</em> infection who completed the regimen without early vomiting and returned for follow-up, the microbiologic cure rates were 100 percent (95% CI 98.5-100) with azithromycin plus gentamicin and 99.5 percent (95% CI 97.6-100) for azithromycin plus gemifloxacin. Both regimens resulted in 100 percent cure of anorectal infections, but the number (n = 6) was small in this trial. In another study evaluating gentamicin (240 mg once) plus azithromycin (2 g orally once), all of the 40 participants identified with anorectal infection who received that regimen had microbiologic and clinical cure at that site [<a href="#rid83">83</a>].</p><p>However, in another trial, 720 men and women with uncomplicated gonococcal infection were randomly assigned to receive IM <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (240 mg once) or <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (500 mg once), each in combination with <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (1 g orally once) [<a href="#rid84">84</a>]. Gentamicin resulted in a lower rate of <em>N. gonorrhoeae</em> clearance (based on NAAT) at all sites compared with ceftriaxone (91 versus 98 percent, adjusted risk difference -6.4 percent; 95% CI -10.4 to -2.4), with particularly low rates at pharyngeal (80 versus 96 percent) and rectal sites (90 versus 98 percent). It is unknown whether use of the higher dose of azithromycin (2 g orally once) would have resulted in a higher cure rate. </p><p>There are several other drawbacks to these regimens. In addition to the GI side effects, the volume of <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> used for IM injection (two 3 mL doses) may make the <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> plus gentamicin combination unacceptable to some patients. The combination of <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">gemifloxacin</a> and azithromycin may also have potential drug interactions (ie, prolonged QT interval) and increase the risk of <em>Clostridioides difficile</em> colitis with inclusion of a fluoroquinolone. These issues should be considered when selecting an alternate regimen. </p><p>While a 2 g single oral dose of <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> monotherapy could treat both gonorrhea and chlamydia infections, it is not a recommended regimen due to increasing gonococcal drug resistance to azithromycin [<a href="#rid1">1</a>]. In a large randomized controlled trial, the 2 g dose had a cure rate of 99 percent (95% CI 97.9-100 percent), equivalent to that reported with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, but was associated with GI side effects in 35 percent [<a href="#rid85">85</a>]. A lower dose of azithromycin is not adequately effective against gonococcal infections. In a systematic review of studies in which azithromycin was used for treatment of uncomplicated urogenital infection, the aggregate cure rate for the 1 g dose fell just below the 95 percent cure rate, the efficacy threshold for gonorrhea [<a href="#rid86">86</a>]. </p><p class="headingAnchor" id="H195635386"><span class="h3">Spectinomycin</span><span class="headingEndMark"> — </span>Spectinomycin (2 g IM) is a safe and effective parenteral alternate for patients with genitourinary infection and a severe beta-lactam allergy that precludes cephalosporin use, but it is not available in the United States and its availability elsewhere is limited [<a href="#rid87">87</a>]. Spectinomycin should not be used for treatment of pharyngeal infection, as it has poor penetration of the Waldeyer tonsillar ring and has been associated with low cure rates at this site [<a href="#rid4">4</a>]. </p><p>If spectinomycin is used, additional therapy for chlamydia is warranted if coinfection has not been ruled out. (See <a class="local">'Presumptive treatment for chlamydia'</a> above.)</p><p class="headingAnchor" id="H1117033"><span class="h1">OTHER GONOCOCCAL INFECTIONS</span></p><p class="headingAnchor" id="H7889046"><span class="h2">Pharyngeal infection</span><span class="headingEndMark"> — </span>Pharyngeal <em>N. gonorrhoeae</em> infection may serve as an important reservoir of infection and contribute to ongoing transmission [<a href="#rid88">88,89</a>]. First-line treatment of pharyngeal infection is the same as for urogenital and anorectal infection, with a single high dose of intramuscular (IM) <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> and presumptive treatment of chlamydia, as detailed above. (See <a class="local">'Preferred regimen'</a> above.) </p><p>However, the optimal alternative regimens for pharyngeal infection are less clear. The alternative single-agent regimens (<a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a>, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>, and spectinomycin) are associated with low rates of gonococcal eradication in the pharynx and should not be used [<a href="#rid3">3,90</a>]. For individuals with pharyngeal infection who have a beta-lactam allergy, options depend on the type of allergy and could still include use of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>, possibly with a test-dose procedure or following skin testing. (See  <a class="medical medical_review" href="/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients", section on 'Our approach'</a> and  <a class="medical medical_review" href="/d/html/13536.html" rel="external">"Immediate cephalosporin hypersensitivity: Allergy evaluation, skin testing, and cross-reactivity with other beta-lactam antibiotics", section on 'Use of related antibiotics in cephalosporin-allergic patients'</a>.) </p><p><a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> plus <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> may be an effective alternative regimen for pharyngeal infection, but it should be reserved for patients with a severe beta-lactam allergy that precludes cephalosporin use. In an open-label randomized trial conducted in the Czech Republic that included 143 patients with pharyngeal and/or rectal gonorrhea, gentamicin 240 mg plus azithromycin 2 g resulted in 100 percent clinical and microbiologic cure rates, the same as with a <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> 500 mg-based regimen [<a href="#rid83">83</a>]. However, in another randomized controlled trial from the United Kingdom, cure rates with gentamicin 240 mg plus azithromycin were lower than with ceftriaxone 500 mg with azithromycin (80 versus 96 percent, respectively) [<a href="#rid84">84</a>].</p><p>A test of cure is recommended for <strong>all</strong> pharyngeal gonococcal infections, regardless of treatment regimen used, because of the challenges to effective treatment at this site [<a href="#rid1">1</a>]. (See <a class="local">'Test of cure'</a> below.)</p><p>Data regarding the optimal therapy of pharyngeal gonococcal infection are limited [<a href="#rid91">91,92</a>]. Pharyngeal infections appear to be more difficult to cure [<a href="#rid72">72,91</a>]. This issue was well illustrated in a meta-analysis of 144 controlled and uncontrolled trials, which found that standard antimicrobial therapy led to cure rates of 79 percent for pharyngeal infections in men compared with 98 and 95 percent for urethral and rectal infections, respectively [<a href="#rid72">72</a>]. </p><p>Theories have been proposed to explain the lower cure rate for pharyngeal infections:</p><p class="bulletIndent1"><span class="glyph">●</span>Pharyngeal isolates are "naturally" less susceptible to antimicrobials, possibly due to the exchange of antimicrobial resistance genes with commensal <em>Neisseria</em> spp. Pharyngeal gonorrhea is mostly asymptomatic, and gonococci and commensal <em>Neisseria</em> spp can coexist for long time periods in the pharynx and share genetic material [<a href="#rid93">93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anatomically, Waldeyer tonsillar ring is characterized by a crypt system consisting of a highly complex network of canals with specialized stratified squamous epithelium [<a href="#rid94">94</a>]. Bacterial infection can be associated with bacterial "plugs" within the crypts that make treatment more difficult. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antimicrobials may work less effectively for asymptomatic pharyngeal gonorrhea due to absence of inflammation at the mucosal surface of the pharynx. The penetration of antibiotics into the oropharyngeal mucosa is a complex process, in which the presence of inflammation and antimicrobial pharmacokinetic properties are important factors to consider [<a href="#rid95">95</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune defense mechanisms are less effective at the mucosal surface of the pharynx than at other sites, and eradication at that site is therefore more dependent upon the efficacy of the antimicrobial agent.</p><p></p><p>Gargling with <a class="drug drug_general" data-topicid="9031" href="/d/drug information/9031.html" rel="external">antiseptic mouthwash</a> should not be relied on for treatment or prevention of pharyngeal gonococcal infection. Although one trial suggested that gargling with alcohol-containing mouthwash could reduce gonococcal growth from pharyngeal cultures [<a href="#rid96">96</a>], a subsequent trial found no difference in pharyngeal gonococcal infection rates among men who have sex with men who were randomly assigned to receive either alcohol-containing or non-alcohol-containing mouthwash for 12 weeks [<a href="#rid97">97</a>].</p><p class="headingAnchor" id="H2209671403"><span class="h2">Rectal infection</span><span class="headingEndMark"> — </span>Treatment for <em>N. gonorrhoeae</em> rectal infection is the same as for urogenital infection, with a single high dose of IM <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> and presumptive treatment of chlamydia, as detailed elsewhere. (See <a class="local">'Preferred regimen'</a> above.) </p><p>Regimens recommended for urogenital infection are highly effective for rectal infection as well. In a meta-analysis that included 1813 cases of rectal gonorrhea treated with various regimens, pooled microbiologic cure rates with ceftriaxone-based regimens were 100 percent [<a href="#rid98">98</a>]. Untreated rectal <em>N. gonorrhoeae</em> infection can serve as a reservoir for transmission [<a href="#rid99">99,100</a>]. As an example, the medial duration of rectal gonorrhea in a prospective, longitudinal study involving 140 men who have sex with men (MSM) was nine weeks [<a href="#rid101">101</a>]. </p><p>Patients with acute proctitis associated with <em>N. gonorrhoeae </em>also warrant evaluation and potentially empiric therapy for other sexually transmitted infections (STIs). The approach to evaluation and management of proctitis is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3730.html" rel="external">"Evaluation of anorectal symptoms in men who have sex with men", section on 'Proctitis'</a>.) </p><p class="headingAnchor" id="H7889060"><span class="h2">Conjunctivitis</span><span class="headingEndMark"> — </span>All patients with documented or suspected gonococcal conjunctivitis should be evaluated emergently by an ophthalmologist. Gonococcal conjunctivitis is treated with a single 1 g IM dose of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> and presumptive treatment for chlamydia infection (see <a class="local">'Presumptive treatment for chlamydia'</a> above). In a small study of 13 patients with culture-proven, non-neonatal gonococcal conjunctivitis, a single 1 g IM injection of ceftriaxone effectively treated all participants [<a href="#rid102">102</a>]. </p><p>A topical fluoroquinolone, <a class="drug drug_general" data-topicid="9929" href="/d/drug information/9929.html" rel="external">saline</a> irrigation, and daily monitoring are also recommended because of the risk of corneal involvement and perforation [<a href="#rid103">103</a>]. If corneal involvement is identified or cannot be excluded because of lid and conjunctival swelling, some experts recommend that the patient be hospitalized and treated with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> 1 g intravenously every 12 to 24 hours until resolution. </p><p>The clinical manifestations and diagnosis of gonococcal conjunctivitis are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/6907.html" rel="external">"Conjunctivitis", section on 'Hyperacute bacterial conjunctivitis'</a>.)</p><p class="headingAnchor" id="H7889074"><span class="h2">Epididymitis</span><span class="headingEndMark"> — </span><em>N. gonorrhoeae</em> or <em>C. trachomatis</em> are the most frequent pathogens in epididymitis among sexually active men &lt;35 years of age, and empiric treatment of acute epididymitis covers these organisms [<a href="#rid104">104</a>]. Management of patients with acute epididymitis is discussed elsewhere.</p><p class="headingAnchor" id="H1117152"><span class="h2">Pelvic inflammatory disease (PID)</span><span class="headingEndMark"> — </span><em>N. gonorrhoeae</em> is rarely documented as the causal pathogen in PID, but empiric treatment for this pathogen is an important component of PID management because the organism may be difficult to recover when it has ascended to the upper tract. The treatment of PID is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents"</a>.)</p><p class="headingAnchor" id="H14405271"><span class="h2">Disseminated gonococcal infection</span><span class="headingEndMark"> — </span>The management of septic arthritis due to <em>N. gonorrhoeae</em> and other manifestations of disseminated gonococcal infection is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7603.html" rel="external">"Disseminated gonococcal infection", section on 'Management'</a>.)</p><p class="headingAnchor" id="H279604"><span class="h1">SPECIFIC POPULATIONS</span></p><p class="headingAnchor" id="H279612"><span class="h2">Penicillin-allergic patients</span><span class="headingEndMark"> — </span>The management of the penicillin-allergic patient depends on the clinical suspicion of true allergy and the type of the allergy (eg, morbilliform rash versus IgE-mediated reactions, such as urticaria). Treatment with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is likely safe if the patient only has a history of rash without IgE manifestations. (See  <a class="medical medical_review" href="/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients", section on 'Management of mild reactions WITHOUT history of features of immediate allergy (minimal risk of immediate allergy)'</a>.)</p><p>Although true IgE-mediated penicillin allergy is rare, for those with a history concerning for an IgE-mediated reaction, options for treatment depend upon how urgently treatment is needed, how severe the past reaction was, and whether consultation with an allergist for skin testing is readily available  (<a class="graphic graphic_algorithm graphicRef112936" href="/d/graphic/112936.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/d/html/111361.html" rel="external">"Choice of antibiotics in penicillin-allergic hospitalized patients", section on 'Management of reactions WITH features of immediate allergy (some risk)'</a>.)</p><p>Alternate treatment choices among patients who have urogenital or anogenital gonococcal infection and cannot use a beta-lactam include spectinomycin (where available), or <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> (2 g as a single oral dose) combined with either <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> (240 intramuscularly once) or, if available, <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">gemifloxacin</a> (320 mg orally once). (See <a class="local">'Alternate regimens'</a> above.)</p><p>If molecular tests that can detect fluoroquinolone resistance are available, a single dose of <a class="drug drug_general" data-topicid="9267" href="/d/drug information/9267.html" rel="external">ciprofloxacin</a> 500 mg orally is an effective option when a fluoroquinolone-susceptible <em>N. gonorrhoeae</em> infection is confirmed [<a href="#rid62">62</a>]. However, these tests are not widely available. (See <a class="local">'Fluoroquinolones'</a> above.)</p><p>For non-pregnant individuals with pharyngeal infection who cannot use a beta-lactam, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> plus <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> can be considered as an alternative regimen. (See <a class="local">'Pharyngeal infection'</a> above.)</p><p class="headingAnchor" id="H279639"><span class="h2">Pregnant women</span><span class="headingEndMark"> — </span>Pregnant women with uncomplicated gonorrheal infection should be treated with the same preferred regimen as the general population. (See <a class="local">'"High" dose intramuscular (IM) ceftriaxone'</a> above.)</p><p>Presumptive treatment for chlamydia (ie, if coinfection has not been ruled out) should be with <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> rather than <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>. (See  <a class="medical medical_review" href="/d/html/7579.html" rel="external">"Treatment of <i>Chlamydia trachomatis</i> infection", section on 'Pregnant individuals'</a>.) </p><p>If a pregnant patient has a severe IgE-mediated allergy to cephalosporins, desensitization procedures should be employed prior to administration. </p><p>If desensitization cannot be performed or the severe beta-lactam allergy otherwise precludes a cephalosporin, <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> plus <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> can be used as an alternate regimen for urogenital or anorectal infection during pregnancy. In pregnant women with a severe beta-lactam allergy and pharyngeal gonorrhea, infectious disease consultation is warranted. A test of cure is recommended if a pregnant patient is treated with an alternative regimen. (See <a class="local">'Test of cure'</a> below.)</p><p>All individuals, including pregnant women, should be retested following treatment within three months; pregnant women who are at continued high risk for gonorrhea should be tested again during the third trimester [<a href="#rid1">1</a>]. (See <a class="local">'Retesting'</a> below.)</p><p>All pregnant women with pelvic inflammatory disease should be hospitalized and given parenteral antibiotics, due to the potential complications of infection resulting in adverse pregnancy outcomes. (See  <a class="medical medical_review" href="/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents"</a>.)</p><p class="headingAnchor" id="H4144011"><span class="h1">PATIENT COUNSELING</span></p><p class="headingAnchor" id="H4144073"><span class="h2">Sexual activity</span><span class="headingEndMark"> — </span>Although gonococci are eliminated from the genital tract within one day after successful treatment [<a href="#rid105">105</a>], patients are generally counseled to avoid sexual activity until seven days following treatment initiation [<a href="#rid1">1</a>]. Patients should only resume having sex after symptoms have resolved and sex partners have been treated. (See <a class="local">'Management of sexual partners'</a> below.)</p><p class="headingAnchor" id="H4144118"><span class="h2">Screen for HIV and other STIs</span><span class="headingEndMark"> — </span>As infection with one sexually transmitted infection (STI) increases the risk of infection with others, individuals diagnosed with <em>N. gonorrhoeae</em> infection should be tested for other STIs, including HIV, chlamydia, and syphilis [<a href="#rid1">1</a>]. Screening for viral hepatitides may also be warranted. Screening for STIs is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7596.html" rel="external">"Screening for sexually transmitted infections"</a> and  <a class="medical medical_review" href="/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection"</a>.)</p><p>In particular, persons with incident gonorrhea are at high risk for HIV infection [<a href="#rid106">106-108</a>]. One study demonstrated that 27 percent of persons who had recently acquired HIV infection (n = 191) were diagnosed with gonorrhea in the 12 months preceding HIV acquisition [<a href="#rid109">109</a>]. Pre-exposure prophylaxis against HIV should be considered for individuals with recent gonorrhea diagnosis who test negative for HIV. (See  <a class="medical medical_review" href="/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis"</a>.) </p><p class="headingAnchor" id="H4144362"><span class="h2">Pregnancy testing</span><span class="headingEndMark"> — </span>Women with reproductive potential and urogenital gonococcal infection should undergo pregnancy testing.</p><p class="headingAnchor" id="H22560004"><span class="h1">PATIENT FOLLOW-UP</span></p><p class="headingAnchor" id="H22560034"><span class="h2">Test of cure</span><span class="headingEndMark"> — </span>Patients who have resolution of symptoms following treatment for uncomplicated urogenital or anorectal gonococcal infections do not need to return for a test of cure [<a href="#rid1">1</a>]. However, the United States Centers for Disease Control and Prevention (CDC) recommends that a test of cure be performed in all individuals with oropharyngeal gonococcal infection.</p><p>Test of cure can be with either culture or nucleic acid amplification tests (NAATs) conducted 7 to 14 days following therapy [<a href="#rid1">1</a>]. Culture is ideal for test of cure as it also allows for susceptibility testing if there is growth of <em>N. gonorrhoeae</em>; however, it is less readily available than NAAT. If NAAT is performed as test of cure, it should be done with sufficient time after treatment (ie, closer to 14 days after treatment) to avoid false-positive results from detection of nonviable organisms that may not represent persistent infection [<a href="#rid110">110,111</a>]. Individuals with a positive NAAT test of cure should also undergo confirmatory culture, if possible, prior to repeat treatment, and all positive culture tests of cure should be submitted for susceptibility testing. In the absence of risk for reinfection, patients with a positive test of cure should be considered as treatment failures. </p><p>The utility of culture as a follow-up to positive NAAT was illustrated in a study in which 190 men who have sex with men (MSM), among whom there were 100 pharyngeal and 100 rectal gonorrhea infections, were retested with NAAT at the infected sites following treatment with <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> and <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> [<a href="#rid112">112</a>]. At days 7 and 14 after therapy, 13 and 8 percent of pharyngeal specimens and 6 and 8 percent of rectal specimens were positive for persistent <em>N. gonorrhoeae</em> deoxyribonucleic acid (DNA), respectively. Persistent NAAT positivity was associated with higher baseline minimum inhibitory concentrations (MICs) to ceftriaxone and azithromycin. However, all specimens except for one rectal sample at 14 days were culture negative, and one case was a documented reinfection. The clinical significance of the persistent NAAT positivity is unclear; it may represent nonviable genetic material, or it could reflect a low level of pathogen persistence that culture is not sensitive enough to detect.</p><p class="headingAnchor" id="H2836827"><span class="h2">Monitoring for and managing treatment failure</span><span class="headingEndMark"> — </span>Patients should be instructed to return to care for evaluation for treatment failure and antimicrobial resistance if they experience persistent or recurrent symptoms soon (eg, three to five days) after completing therapy for gonorrhea. Treatment failure is also suspected in individuals who have a positive test of cure. In particular, MSM appear to have a higher prevalence of antimicrobial-resistant gonococcal infections than men who have sex exclusively with women [<a href="#rid15">15</a>].</p><p>Many of these cases are due to reinfection or other sexually transmitted infections, which should be assessed for, since rates of coinfection (eg, <em>C. trachomatis</em>, <em>M. genitalium</em>) are high (see <a class="local">'Postgonococcal urethritis'</a> below). If reinfection seems likely, the patient can be treated with the usual preferred regimen. (See <a class="local">'"High" dose intramuscular (IM) ceftriaxone'</a> above.)</p><p>If reinfection is unlikely (eg, if there were no additional sexual exposures following treatment), treatment failure and resistance are a greater concern. Relevant specimens (eg, urethral, oropharyngeal, and/or rectal samples depending on exposure) should be submitted for culture and NAAT for <em>N. gonorrhoeae</em> detection, and culture isolates should be sent for susceptibility testing [<a href="#rid1">1</a>].</p><p>Any case of suspected treatment failure (isolation of <em>N. gonorrhoeae</em> following therapy and low suspicion for repeat infection) or gonococcal isolates with reduced susceptibility to cephalosporins (MIC ≥0.5 mcg/mL) should be reported to governmental public health agencies. In the United States, cases should be reported to the CDC at 404-718-5447 and through state and local public health authorities. Isolates should also be submitted to CDC for susceptibility testing if not already performed.</p><p>The optimal management of suspected treatment failure to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is uncertain, as there are minimal data evaluating efficacy of different regimens in this situation; consultation with an expert in treating sexually transmitted infections is warranted [<a href="#rid1">1</a>]. Ideally, therapy should be guided by susceptibility testing. Higher antibiotic doses may be able to overcome moderately elevated MICs in some cases of treatment failure (eg, using 1 g of ceftriaxone if 500 mg was initially used) [<a href="#rid74">74</a>]. If an alternative regimen (eg, <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a>) was initially used, ceftriaxone 500 mg once may be adequate. <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">Azithromycin</a> (2 g) plus <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a> and <a class="drug drug_general" data-topicid="8760" href="/d/drug information/8760.html" rel="external">gemifloxacin</a> in combination are other potential options for isolates with decreased cephalosporin susceptibilities, although side effects or availability may limit their use. (See <a class="local">'Azithromycin plus gentamicin or gemifloxacin'</a> above.) </p><p>Other agents not typically used for gonorrhea may be future options for highly resistant infections, if more data further support their use. Three days of intravenous <a class="drug drug_general" data-topicid="8675" href="/d/drug information/8675.html" rel="external">ertapenem</a> successfully eradicated a <em>N. gonorrhoeae</em> strain with an elevated MIC to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> (0.5 mcg/mL) and high-level <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> resistance that was isolated from a heterosexual man who failed therapy with ceftriaxone 1 g intramuscular as well as spectinomycin [<a href="#rid37">37</a>]. Although there are no established ertapenem breakpoints for <em>N. gonorrhoeae</em>, ertapenem was chosen because the MIC of this isolate was low. Other studies have documented ertapenem efficacy for non-resistant <em>N. gonorrhoeae</em>. In a randomized trial, microbiologic clearance rates for anorectal or urogenital gonorrhea were similar with a single dose of ertapenem 1 g versus ceftriaxone 500 mg, each given intramuscularly (99 versus 100 percent) [<a href="#rid113">113</a>]. </p><p>Test of cure with both culture and NAAT is recommended following retreatment [<a href="#rid1">1</a>]. (See <a class="local">'Test of cure'</a> above.)</p><p class="headingAnchor" id="H22560061"><span class="h2">Retesting</span><span class="headingEndMark"> — </span>Patients diagnosed with gonorrhea are at risk for repeat infection as well as infections with other sexually transmitted infections, including HIV. All patients should return at three months after treatment (or, if that is not possible, within 12 months of treatment) for retesting for <em>N. gonorrhoeae </em>infection. (See  <a class="medical medical_review" href="/d/html/15893.html" rel="external">"Clinical manifestations and diagnosis of <i>Neisseria gonorrhoeae </i>infection in adults and adolescents"</a>.)</p><p class="headingAnchor" id="H7889102"><span class="h1">POSTGONOCOCCAL URETHRITIS</span><span class="headingEndMark"> — </span>Postgonococcal urethritis refers to symptoms that persist after successful eradication of gonococcal infection. Postgonococcal urethritis may be related to other untreated copathogens, such as chlamydia, trichomonas, or <em>M. genitalium</em>. Herpes simplex virus (HSV) may also be a causative agent, although HSV is often distinguished from these other pathogens on physical examination. Evaluation and management of persistent symptoms after treatment for urethritis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/86698.html" rel="external">"Urethritis in adult males", section on 'Recurrent or persistent symptoms'</a>.)</p><p class="headingAnchor" id="H7889109"><span class="h1">PUBLIC HEALTH ISSUES</span></p><p class="headingAnchor" id="H4144418"><span class="h2">Reporting</span><span class="headingEndMark"> — </span>In the United States, gonorrhea is reportable to public health authorities in every state and the District of Columbia; case reporting may be performed by the laboratory or provider. </p><p class="headingAnchor" id="H4144433"><span class="h2">Management of sexual partners</span><span class="headingEndMark"> — </span>All individuals who have had sexual contact with patients diagnosed with <em>N. gonorrhoeae</em> within the past 60 days of the diagnosis should be evaluated and treated. If the patient had no sexual contact within the 60 days prior to diagnosis, the most recent sexual partner should be evaluated and treated.</p><p>Sexual partners, particularly women, may be asymptomatic and, unless treated, will reinfect the index patient or spread infection to other partners. In the United States, the traditional approach has been to utilize members of a public health field team to notify exposed sex partners, but many health departments are no longer tracing these partners due to staffing shortages and lack of resources [<a href="#rid114">114</a>]. In lieu of public health advocacy, patients should be asked to notify their partners of the need for medical evaluation and treatment (partner notification [PN]). Unfortunately, this approach is sometimes inefficient and may result in few treated partners [<a href="#rid114">114</a>]. In some situations, expedited partner therapy may be an alternative strategy for partner management.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expedited partner therapy (EPT) </strong>– This refers to the clinical practice of treating the sex partners of patients diagnosed with sexually transmitted infections (STIs) without formal evaluation of the partner(s), by providing prescriptions or medications to the patient to deliver to the partner(s). Although clinical evaluation and treatment for gonorrhea are preferred, we suggest EPT for heterosexual contacts of patients with gonorrhea in whom clinical evaluation is unlikely. EPT is not routinely recommended for men who have sex with men (MSM) because of a high risk for coexisting infections, especially undiagnosed HIV infection, in their partners, and EPT does not offer opportunities to counsel or evaluate partners regarding this risk. Additionally, MSM may be at greater risk of pharyngeal infection, for which there is a risk of treatment failure with <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> as the oral agent used for EPT (see <a class="local">'Pharyngeal infection'</a> above). If EPT is used for MSM, they should be made aware of these risks. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For partners of patients with gonorrhea, oral <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> 800 mg orally once (plus presumptive treatment for chlamydia if not ruled out in the index patient) is used for EPT [<a href="#rid1">1</a>]. Partners should also be given written information about gonorrhea, the importance of therapy, and instructions to present to medical care for symptoms or adverse effects. </p><p></p><p class="bulletIndent1">In the United States, the legal status of EPT remains an area of uncertainty and currently depends on whether individual state regulations allow health care providers to provide a prescription for a patient's partner without a prior evaluation or relationship with the partner. The practice of EPT is permissible in the majority of states [<a href="#rid115">115</a>]. The legal status of EPT options can be found at the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cdc.gov%2Fstd%2Fept%2Flegal%2Fdefault.htm&amp;token=6%2BIxsHSK5sOfdv7cVd5tMSzlAbMRBvBxyZ5xR7LelSjRfsvcEsKhGcWnQUyzsWJQyIfH4DxqYxsIm1DN%2Blc9ew%3D%3D&amp;TOPIC_ID=15892" target="_blank">United States Centers for Disease Control and Prevention website</a>.</p><p></p><p class="bulletIndent1">Advocates for EPT cite its overall positive impact on reducing rates of reinfection and increasing the proportion of patients receiving therapeutic interventions [<a href="#rid116">116</a>]. In randomized trials, EPT was more effective than traditional partner notification programs (ie, the patient notifies the partner of the need for evaluation and treatment) in reducing persistent or recurrent urogenital gonococcal infection among index patients [<a href="#rid44">44,117</a>]. However, limitations of this strategy include lost opportunities for STI/HIV screening and risk of unmonitored adverse events related to antibiotic administration [<a href="#rid114">114,117</a>]. </p><p></p><p class="headingAnchor" id="H3963439662"><span class="h1">INVESTIGATIONAL STRATEGIES</span><span class="headingEndMark"> — </span>Several novel agents in development have good in vitro activity against <em>N. gonorrhoeae </em>and drug-resistant strains, but<em> </em>clinical data are limited. In one early clinical trial, a single dose of gepotidacin, a novel bacterial topoisomerase inhibitor, resulted in microbiologic cure in ≥95 percent of 69 patients with uncomplicated urogenital gonorrhea; however, three treatment failures were due to a common gene mutation associated with gepotidacin resistance [<a href="#rid118">118</a>]. A single dose of zoliflodacin, a novel oral spiropyrimidinetrione antibiotic that inhibits DNA synthesis, also resulted in high rates of microbiologic cure with a favorable safety profile in a trial of 141 patients with culture-confirmed uncomplicated urogenital gonococcal infection (96 versus 100 percent cure with a single 500 mg <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> injection) [<a href="#rid119">119</a>]. It was associated with lower eradication rates for pharyngeal infection, similar to the pattern of lower cure rates at this anatomic site with other agents [<a href="#rid72">72</a>]. Global phase III trials are underway for both investigational agents. </p><p>Given the time between new drug development and its approval and licensure, vaccine development for <em>N. gonorrhoeae </em>is also an important initiative. Vaccines to prevent gonorrhea are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7595.html" rel="external">"Prevention of sexually transmitted infections", section on 'Vaccines'</a>.)</p><p class="headingAnchor" id="H2492752314"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H7889123"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/15379.html" rel="external">"Patient education: Chlamydia and gonorrhea (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/d/html/4020.html" rel="external">"Patient education: Gonorrhea (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H7889919"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of therapy</strong> – Antimicrobial treatment is required for all patients diagnosed with gonorrhea. It is a highly transmissible infection that can result in serious sequelae if untreated, even in asymptomatic individuals. The role of treatment is to resolve symptoms if present, prevent complications of infection, and decrease transmission to others. (See <a class="local">'Therapeutic principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Selecting a treatment regimen</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">Ceftriaxone</a><strong> as preferred therapy for gonorrhea </strong>– Ceftriaxone is standard of care for treatment of gonorrhea. It is highly effective against susceptible <em>N. gonorrhoeae.</em> Although isolates with decreasing susceptibility and resistance to cephalosporins have emerged, ceftriaxone has the lowest rates of gonococcal drug resistance. (See <a class="local">'Antibiotic resistance'</a> above.)</p><p></p><p class="bulletIndent2">For suspected or confirmed uncomplicated gonococcal infection, we suggest a single intramuscular dose of <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> rather than any other regimen (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). We suggest a ceftriaxone dose of 500 mg (or 1 g for patients ≥150 kg) rather than lower doses  (<a class="graphic graphic_table graphicRef141567" href="/d/graphic/141567.html" rel="external">table 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Higher doses are used because of decreasing susceptibility. (See <a class="local">'"High" dose intramuscular (IM) ceftriaxone'</a> above and <a class="local">'Rectal infection'</a> above and <a class="local">'Pharyngeal infection'</a> above.)</p><p></p><p class="bulletIndent2">Uncomplicated infection is generally limited to the urogenital tract, anorectal tract, and/or oropharynx. Other regimens are used for complicated infections, which are characterized by disseminated infection (eg, bacteremia, gonococcal arthritis) or ascending spread to other organs (eg, pelvic inflammatory disease). (See <a class="local">'Definition of uncomplicated infection'</a> above and  <a class="medical medical_review" href="/d/html/7603.html" rel="external">"Disseminated gonococcal infection", section on 'Management'</a> and  <a class="medical medical_review" href="/d/html/7585.html" rel="external">"Pelvic inflammatory disease: Treatment in adults and adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Plus presumptive treatment of chlamydia</strong> – Because of the high rate of coinfection, we also suggest presumptive treatment for <em>C. trachomatis</em> for individuals with gonorrhea unless it has been excluded through microbiologic testing (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">Doxycycline</a> 100 mg twice daily for seven days is the preferred regimen for treatment of <em>C. trachomatis</em> in nonpregnant individuals. Alternatives are listed in the table  (<a class="graphic graphic_table graphicRef141567" href="/d/graphic/141567.html" rel="external">table 1</a>). (See <a class="local">'Presumptive treatment for chlamydia'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role for</strong> <strong>alternative regimens</strong> – These include other cephalosporins (including <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a>) and high-dose <a class="drug drug_general" data-topicid="9041" href="/d/drug information/9041.html" rel="external">azithromycin</a> with <a class="drug drug_general" data-topicid="8489" href="/d/drug information/8489.html" rel="external">gentamicin</a>, but all have drawbacks that limit their utility  (<a class="graphic graphic_table graphicRef141567" href="/d/graphic/141567.html" rel="external">table 1</a>). They should be reserved for patients who have urogenital or anorectal infection and cannot take <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> because of unavailability or severe allergies. There is a high risk of failure with alternative regimens for oropharyngeal infection. (See <a class="local">'Alternate regimens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Test for and prevent other sexually transmitted infections (STIs)</strong> – Individuals diagnosed with gonorrhea should be tested for other STIs, including HIV, chlamydia, and syphilis, if not already done at the time of diagnosis  (<a class="graphic graphic_table graphicRef103391" href="/d/graphic/103391.html" rel="external">table 2</a>). (See <a class="local">'Screen for HIV and other STIs'</a> above.)</p><p></p><p class="bulletIndent1">Individuals newly diagnosed with gonorrhea are at increased risk for HIV infection and should be evaluated for pre-exposure prophylaxis against HIV if they test negative. (See  <a class="medical medical_review" href="/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing sex partners</strong> – Treatment of sex partners is essential for preventing reinfection and controlling the spread of infection. The following individuals should be presumptively treated for gonorrhea<em>:</em></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Any sex partner within 60 days prior to the diagnosis of infection</p><p class="bulletIndent2"><span class="glyph">•</span>The most recent sex partner if sex last occurred &gt;60 days before infection</p><p></p><p class="bulletIndent1">For sex partners of patients with documented gonococcal infection who are unlikely to present for evaluation and treatment, we suggest expedited partner therapy (EPT) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). This entails providing a single dose of oral <a class="drug drug_general" data-topicid="9216" href="/d/drug information/9216.html" rel="external">cefixime</a> 800 mg (plus presumptive treatment for chlamydia if not ruled out in the index patient  (<a class="graphic graphic_table graphicRef141567" href="/d/graphic/141567.html" rel="external">table 1</a>)) to sex partners. </p><p></p><p class="bulletIndent1">The exception is in men who have sex with men, for whom we prefer direct evaluation and management after notification by the patient or public health department because of the high risk for coexisting infections, including HIV. (See <a class="local">'Management of sexual partners'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up testing </strong>– This depends on the site of infection. (See <a class="local">'Patient follow-up'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Urogenital or anorectal infection:</strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If symptoms resolve with initial treatment, there is no need to test for cure. We retest after three months to evaluate for reinfection.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If symptoms persist or recur shortly (eg, three to five days) after treatment completion, we retest for gonorrhea and other STIs to evaluate for coinfections, treatment failure, and reinfection.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Oropharyngeal infection:</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We perform test of cure at the oropharynx, regardless of symptom resolution, at 7 to 14 days post-treatment to ensure eradication.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We also retest after three months to evaluate for reinfection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment failure</strong> – When evaluating suspected treatment failure, we submit specimens from all sites of exposure for both culture and nucleic acid amplification testing (NAAT)<em>,</em> and culture isolates should be sent for susceptibility testing. These cases should also be reported to governmental public health agencies. The optimal management of suspected treatment failure to <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a> is uncertain. (See <a class="local">'Monitoring for and managing treatment failure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Specific circumstances </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pregnancy</strong> – Uncomplicated gonorrheal infection during pregnancy is treated the same as in the general population. Pregnant individuals should undergo retesting three months following therapy, and those at continued high risk for gonococcal infection should be retested during the third trimester. (See <a class="local">'Pregnant women'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Penicillin allergy</strong> – The management of the penicillin-allergic patient depends upon the clinical suspicion of true allergy and the type of the allergy (eg, morbilliform rash versus IgE-mediated reactions, such as urticaria). Most patients with a penicillin allergy can still use <a class="drug drug_general" data-topicid="9229" href="/d/drug information/9229.html" rel="external">ceftriaxone</a>. (See <a class="local">'Penicillin-allergic patients'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021; 70:1.</a></li><li><a class="nounderline abstract_t">Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008; 148:606.</a></li><li><a class="nounderline abstract_t">Newman LM, Moran JS, Workowski KA. Update on the management of gonorrhea in adults in the United States. Clin Infect Dis 2007; 44 Suppl 3:S84.</a></li><li><a class="nounderline abstract_t">Moran JS, Levine WC. Drugs of choice for the treatment of uncomplicated gonococcal infections. Clin Infect Dis 1995; 20 Suppl 1:S47.</a></li><li><a class="nounderline abstract_t">Datta SD, Sternberg M, Johnson RE, et al. Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002. Ann Intern Med 2007; 147:89.</a></li><li><a class="nounderline abstract_t">Gottlieb SL, Berman SM, Low N. Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection: how much do we know? J Infect Dis 2010; 201 Suppl 2:S156.</a></li><li><a class="nounderline abstract_t">Manhart LE, Broad JM, Golden MR. Mycoplasma genitalium: should we treat and how? Clin Infect Dis 2011; 53 Suppl 3:S129.</a></li><li><a class="nounderline abstract_t">Ross JD, Lewis DA. Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin? Sex Transm Infect 2012; 88:6.</a></li><li class="breakAll">European Centre for Disease Prevention and Control. Gonococcal antimicrobial susceptibility surveillance in Europe, 2013. Stockholm: ECDC; 2015.</li><li class="breakAll">Australian Gonococcal Surveillance Programme annual reports. http://www.health.gov.au/internet/main/publishing.nsf/content/cda-pubs-annlrpt-gonoanrep.htm (Accessed on November 01, 2014).</li><li class="breakAll">World Health Organization. The Gonococcal Antimicrobial Surveillance Programme (GASP) http://www.who.int/reproductivehealth/topics/rtis/gonococcal_resistance/en/ (Accessed on July 10, 2017).</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections. MMWR Morb Mortal Wkly Rep 2007; 56:332.</a></li><li><a class="nounderline abstract_t">Sparling PF. Antibiotic resistance in Neisseria gonorrhoeae. Med Clin North Am 1972; 56:1133.</a></li><li><a class="nounderline abstract_t">Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7:1401.</a></li><li><a class="nounderline abstract_t">Kirkcaldy RD, Zaidi A, Hook EW 3rd, et al. Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010. Ann Intern Med 2013; 158:321.</a></li><li class="breakAll">Massachusetts Department of Public Health. Department of Public Health announces first cases of concerning gonorrhea strain. https://www.mass.gov/news/department-of-public-health-announces-first-cases-of-concerning-gonorrhea-strain (Accessed on March 24, 2023).</li><li><a class="nounderline abstract_t">Day M, Pitt R, Mody N, et al. Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022. Euro Surveill 2022; 27.</a></li><li><a class="nounderline abstract_t">Picker MA, Knoblock RJ, Hansen H, et al. Notes from the Field: First Case in the United States of Neisseria gonorrhoeae Harboring Emerging Mosaic penA60 Allele, Conferring Reduced Susceptibility to Cefixime and Ceftriaxone. MMWR Morb Mortal Wkly Rep 2020; 69:1876.</a></li><li><a class="nounderline abstract_t">Unemo M, Bradshaw CS, Hocking JS, et al. Sexually transmitted infections: challenges ahead. Lancet Infect Dis 2017; 17:e235.</a></li><li><a class="nounderline abstract_t">Brittain C, Childs M, Duley L, et al. Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial. Trials 2016; 17:558.</a></li><li><a class="nounderline abstract_t">Quaye N, Cole MJ, Ison CA. Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime. J Antimicrob Chemother 2014; 69:1568.</a></li><li><a class="nounderline abstract_t">Eyre DW, Sanderson ND, Lord E, et al. Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018. Euro Surveill 2018; 23.</a></li><li><a class="nounderline abstract_t">Schwarcz SK, Zenilman JM, Schnell D, et al. National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project. JAMA 1990; 264:1413.</a></li><li class="breakAll">Sexually Transmitted Disease Surveillance 2020: Gonococcal Isolate Surveillance Project  Profile. https://www.cdc.gov/std/statistics/gisp-profiles/gisp_profiles_national_final.pdf (Accessed on February 17, 2023).</li><li><a class="nounderline abstract_t">Wi T, Lahra MM, Ndowa F, et al. Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action. PLoS Med 2017; 14:e1002344.</a></li><li><a class="nounderline abstract_t">Muratani T, Akasaka S, Kobayashi T, et al. Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan. Antimicrob Agents Chemother 2001; 45:3603.</a></li><li><a class="nounderline abstract_t">Yokoi S, Deguchi T, Ozawa T, et al. Threat to cefixime treatment for gonorrhea. Emerg Infect Dis 2007; 13:1275.</a></li><li><a class="nounderline abstract_t">Barry PM, Klausner JD. The use of cephalosporins for gonorrhea: the impending problem of resistance. Expert Opin Pharmacother 2009; 10:555.</a></li><li><a class="nounderline abstract_t">Singh AE, Gratrix J, Martin I, et al. Gonorrhea Treatment Failures With Oral and Injectable Expanded Spectrum Cephalosporin Monotherapy vs Dual Therapy at 4 Canadian Sexually Transmitted Infection Clinics, 2010-2013. Sex Transm Dis 2015; 42:331.</a></li><li><a class="nounderline abstract_t">Allen VG, Mitterni L, Seah C, et al. Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada. JAMA 2013; 309:163.</a></li><li><a class="nounderline abstract_t">Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55:3538.</a></li><li><a class="nounderline abstract_t">Ohnishi M, Saika T, Hoshina S, et al. Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 2011; 17:148.</a></li><li><a class="nounderline abstract_t">Unemo M, Golparian D, Nicholas R, et al. High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56:1273.</a></li><li class="breakAll">UK Health Security Agency. More cases of antibiotic resistant gonorrhoea identified in England. https://www.gov.uk/government/news/more-cases-of-antibiotic-resistant-gonorrhoea-identified-in-england (Accessed on February 17, 2023).</li><li><a class="nounderline abstract_t">Unemo M, Golparian D, Hestner A. Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010. Euro Surveill 2011; 16.</a></li><li><a class="nounderline abstract_t">Y Chen M, Stevens K, Tideman R, et al. Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia. J Antimicrob Chemother 2013; 68:1445.</a></li><li class="breakAll">Public Health England. Update on investigation of UK case of
Neisseria gonorrhoeae with high-level
resistance to azithromycin and resistance
to ceftriaxone acquired abroad. April 20, 2018. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/701185/hpr1418_MDRGC.pdf.</li><li><a class="nounderline abstract_t">Chisholm SA, Mouton JW, Lewis DA, et al. Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink? J Antimicrob Chemother 2010; 65:2141.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010. MMWR Morb Mortal Wkly Rep 2011; 60:873.</a></li><li><a class="nounderline abstract_t">Martin I, Sawatzky P, Allen V, et al. Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001-2010. Sex Transm Dis 2012; 39:316.</a></li><li><a class="nounderline abstract_t">Ray K, Bala M, Kumari S, Narain JP. Antimicrobial resistance of Neisseria gonorrhoeae in selected World Health Organization Southeast Asia Region countries: an overview. Sex Transm Dis 2005; 32:178.</a></li><li><a class="nounderline abstract_t">Starnino S, GASP-LAC Working Group, Galarza P, et al. Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone. Sex Transm Dis 2012; 39:813.</a></li><li><a class="nounderline abstract_t">Lahra MM, Ryder N, Whiley DM. A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia. N Engl J Med 2014; 371:1850.</a></li><li><a class="nounderline abstract_t">Kissinger P, Mohammed H, Richardson-Alston G, et al. Patient-delivered partner treatment for male urethritis: a randomized, controlled trial. Clin Infect Dis 2005; 41:623.</a></li><li><a class="nounderline abstract_t">Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012; 366:485.</a></li><li><a class="nounderline abstract_t">Whiley DM, Goire N, Lahra MM, et al. The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting. J Antimicrob Chemother 2012; 67:2059.</a></li><li class="breakAll">Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2015: Gonococcal Isolate Surveillance Project (GISP) Supplement and Profiles. Atlanta: U.S. Department of Health and Human Services; 2017. https://www.cdc.gov/std/stats15/gisp2015/GISP-Supplement-AggrFigs_AggrTables_Clinic-Profiles_2015.pdf (Accessed on July 10, 2017).</li><li><a class="nounderline abstract_t">Barbee LA, Soge OO, Katz DA, et al. Increases in Neisseria gonorrhoeae With Reduced Susceptibility to Azithromycin Among Men Who Have Sex With Men in Seattle, King County, Washington, 2012-2016. Clin Infect Dis 2018; 66:712.</a></li><li><a class="nounderline abstract_t">Katz AR, Komeya AY, Soge OO, et al. Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States. Clin Infect Dis 2012; 54:841.</a></li><li><a class="nounderline abstract_t">Katz AR, Komeya AY, Kirkcaldy RD, et al. Cluster of Neisseria gonorrhoeae Isolates With High-level Azithromycin Resistance and Decreased Ceftriaxone Susceptibility, Hawaii, 2016. Clin Infect Dis 2017; 65:918.</a></li><li><a class="nounderline abstract_t">Yuan LF, Yin YP, Dai XQ, et al. Resistance to azithromycin of Neisseria gonorrhoeae isolates from 2 cities in China. Sex Transm Dis 2011; 38:764.</a></li><li><a class="nounderline abstract_t">Tanaka M, Furuya R, Irie S, et al. High Prevalence of Azithromycin-Resistant Neisseria gonorrhoeae Isolates With a Multidrug Resistance Phenotype in Fukuoka, Japan. Sex Transm Dis 2015; 42:337.</a></li><li><a class="nounderline abstract_t">Yasuda M, Hatazaki K, Ito S, et al. Antimicrobial Susceptibility of Neisseria gonorrhoeae in Japan from 2000 to 2015. Sex Transm Dis 2017; 44:149.</a></li><li><a class="nounderline abstract_t">Lo JY, Ho KM, Lo AC. Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance. J Antimicrob Chemother 2012; 67:1422.</a></li><li><a class="nounderline abstract_t">Rowlinson E, Soge OO, Hughes JP, et al. Prior Exposure to Azithromycin and Azithromycin Resistance Among Persons Diagnosed With Neisseria gonorrhoeae Infection at a Sexual Health Clinic: 2012-2019. Clin Infect Dis 2023; 76:e1270.</a></li><li><a class="nounderline abstract_t">Cole MJ, Chisholm SA, Hoffmann S, et al. European surveillance of antimicrobial resistance in Neisseria gonorrhoeae. Sex Transm Infect 2010; 86:427.</a></li><li><a class="nounderline abstract_t">Boslego JW, Tramont EC, Takafuji ET, et al. Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae. N Engl J Med 1987; 317:272.</a></li><li><a class="nounderline abstract_t">Brown LB, Krysiak R, Kamanga G, et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010; 37:169.</a></li><li><a class="nounderline abstract_t">Matoga M, Chen JS, Krysiak R, et al. Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi. Sex Transm Dis 2022; 49:251.</a></li><li><a class="nounderline abstract_t">Kunz AN, Begum AA, Wu H, et al. Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations. J Infect Dis 2012; 205:1821.</a></li><li><a class="nounderline abstract_t">Dillon JA, Parti RP. Fluoroquinolone resistance in Neisseria gonorrhoeae: fitness cost or benefit? J Infect Dis 2012; 205:1775.</a></li><li><a class="nounderline abstract_t">Klausner JD, Bristow CC, Soge OO, et al. Resistance-Guided Treatment of Gonorrhea: A Prospective Clinical Study. Clin Infect Dis 2021; 73:298.</a></li><li><a class="nounderline abstract_t">Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 1998; 351 Suppl 3:5.</a></li><li><a class="nounderline abstract_t">Wang SA, Harvey AB, Conner SM, et al. Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance. Ann Intern Med 2007; 147:81.</a></li><li class="breakAll">British Association for Sexual Health and HIV. BASHH Clinical Effectiveness Group Guidelines. http://www.bashh.org/guidelines (Accessed on December 18, 2020).</li><li class="breakAll">Wang QQ, Zhang RL, Liu QZ, et al. National Guidelines on Diagnosis and Treatment of Gonorrhea in China (2020). Int J Dermatol Venereol https://journals.lww.com/ijdv/fulltext/2020/09000/national_guidelines_on_diagnosis_and_treatment_of.1.aspx (Accessed on January 27, 2022).</li><li><a class="nounderline abstract_t">Chen XS, Yin YP, Li XY. A ROADMAP Plan to Address Research Needs for Gonococcal Antimicrobial Resistance in China. Clin Infect Dis 2019; 68:505.</a></li><li class="breakAll">Japanese Society for Sexually Transmitted Diseases. Guidelines for the diagnosis and treatment of sexually transmitted diseases 2011. Jpn J Sex Transm Dis 2011; 22Suppl: 52–9.</li><li><a class="nounderline abstract_t">Hamasuna R, Yasuda M, Takahashi S, et al. The JAID/JSC guidelines to Clinical Management of Infectious Disease 2017 concerning male urethritis and related disorders. J Infect Chemother 2021; 27:546.</a></li><li><a class="nounderline abstract_t">Bai ZG, Bao XJ, Cheng WD, et al. Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials. Int J STD AIDS 2012; 23:126.</a></li><li><a class="nounderline abstract_t">Connolly KL, Eakin AE, Gomez C, et al. Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Moran JS. Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important? Sex Transm Dis 1995; 22:39.</a></li><li><a class="nounderline abstract_t">Aoki T, Mizushima D, Takano M, et al. Efficacy of 1 g Ceftriaxone Monotherapy Compared to Dual Therapy With Azithromycin or Doxycycline for Treating Extragenital Gonorrhea Among Men Who Have Sex With Men. Clin Infect Dis 2021; 73:1452.</a></li><li><a class="nounderline abstract_t">Fifer H, Natarajan U, Jones L, et al. Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. N Engl J Med 2016; 374:2504.</a></li><li><a class="nounderline abstract_t">Gernert KM, Seby S, Schmerer MW, et al. Azithromycin susceptibility of Neisseria gonorrhoeae in the USA in 2017: a genomic analysis of surveillance data. Lancet Microbe 2020; 1:e154.</a></li><li><a class="nounderline abstract_t">Wind CM, de Vries E, Schim van der Loeff MF, et al. Decreased Azithromycin Susceptibility of Neisseria gonorrhoeae Isolates in Patients Recently Treated with Azithromycin. Clin Infect Dis 2017; 65:37.</a></li><li><a class="nounderline abstract_t">Handsfield HH, McCormack WM, Hook EW 3rd, et al. A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group. N Engl J Med 1991; 325:1337.</a></li><li><a class="nounderline abstract_t">Yang KJ, Kojima N, Bristow CC, Klausner JD. Effectiveness of Cefixime for the Treatment of Neisseria gonorrhoeae Infection at 3 Anatomic Sites: A Systematic Review and Meta-Analysis. Sex Transm Dis 2023; 50:131.</a></li><li><a class="nounderline abstract_t">Gratrix J, Bergman J, Egan C, et al. Retrospective review of pharyngeal gonorrhea treatment failures in Alberta, Canada. Sex Transm Dis 2013; 40:877.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61:590.</a></li><li><a class="nounderline abstract_t">Pandori M, Barry PM, Wu A, et al. Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California. Antimicrob Agents Chemother 2009; 53:4032.</a></li><li><a class="nounderline abstract_t">Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014; 59:1083.</a></li><li><a class="nounderline abstract_t">Rob F, Klubalová B, Nyčová E, et al. Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial. Clin Microbiol Infect 2020; 26:207.</a></li><li><a class="nounderline abstract_t">Ross JDC, Brittain C, Cole M, et al. Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial. Lancet 2019; 393:2511.</a></li><li><a class="nounderline abstract_t">Handsfield HH, Dalu ZA, Martin DH, et al. Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group. Sex Transm Dis 1994; 21:107.</a></li><li><a class="nounderline abstract_t">Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sex Transm Infect 2010; 86:422.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention. Notice to readers: Discontinuation of spectinomycin. MMWR Morb Mortal Wkly Rep 2006; 55:370.</a></li><li><a class="nounderline abstract_t">Bernstein KT, Stephens SC, Barry PM, et al. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men. Clin Infect Dis 2009; 49:1793.</a></li><li><a class="nounderline abstract_t">Marcus JL, Kohn RP, Barry PM, et al. Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the female oropharynx to the male urethra. Sex Transm Dis 2011; 38:372.</a></li><li><a class="nounderline abstract_t">Barbee LA, Soge OO, Morgan J, et al. Gentamicin Alone Is Inadequate to Eradicate Neisseria Gonorrhoeae From the Pharynx. Clin Infect Dis 2020; 71:1877.</a></li><li><a class="nounderline abstract_t">Weinstock H, Workowski KA. Pharyngeal gonorrhea: an important reservoir of infection? Clin Infect Dis 2009; 49:1798.</a></li><li><a class="nounderline abstract_t">Barbee LA, Kerani RP, Dombrowski JC, et al. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis 2013; 56:1539.</a></li><li><a class="nounderline abstract_t">Unemo M. Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge. BMC Infect Dis 2015; 15:364.</a></li><li><a class="nounderline abstract_t">Hellings P, Jorissen M, Ceuppens JL. The Waldeyer's ring. Acta Otorhinolaryngol Belg 2000; 54:237.</a></li><li><a class="nounderline abstract_t">Najjar TA, Alkharfy KM, Saad SY. Mechanism and implication of cephalosporin penetration into oropharyngeal mucosa. J Infect Chemother 2009; 15:70.</a></li><li><a class="nounderline abstract_t">Chow EP, Howden BP, Walker S, et al. Antiseptic mouthwash against pharyngeal Neisseria gonorrhoeae: a randomised controlled trial and an in vitro study. Sex Transm Infect 2017; 93:88.</a></li><li><a class="nounderline abstract_t">Chow EPF, Williamson DA, Hocking JS, et al. Antiseptic mouthwash for gonorrhoea prevention (OMEGA): a randomised, double-blind, parallel-group, multicentre trial. Lancet Infect Dis 2021; 21:647.</a></li><li><a class="nounderline abstract_t">Lo FWY, Kong FYS, Hocking JS. Treatment efficacy for rectal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 2021; 76:3111.</a></li><li><a class="nounderline abstract_t">Chan PA, Robinette A, Montgomery M, et al. Extragenital Infections Caused by Chlamydia trachomatis and Neisseria gonorrhoeae: A Review of the Literature. Infect Dis Obstet Gynecol 2016; 2016:5758387.</a></li><li><a class="nounderline abstract_t">Tao G, Hoover KW, Nye MB, et al. Infrequent Testing of Women for Rectal Chlamydia and Gonorrhea in the United States. Clin Infect Dis 2018; 66:570.</a></li><li><a class="nounderline abstract_t">Barbee LA, Khosropour CM, Soge OO, et al. The Natural History of Rectal Gonococcal and Chlamydial Infections: The ExGen Study. Clin Infect Dis 2022; 74:1549.</a></li><li><a class="nounderline abstract_t">Haimovici R, Roussel TJ. Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone. Am J Ophthalmol 1989; 107:511.</a></li><li class="breakAll">Bagheri N, Wajda B, Calvo C, Durrani A. The Wills Eye Manual: Office and Emergency Room Diagnosis and Treatment of Eye Disease, 7th ed, Wolters Kluwer, Philadelphia 2017.</li><li class="breakAll">Geisler WM and Krieger JN. Epididymitis. In: Sexually Transmitted Diseases, 4, Holmes K, Sparling P, Stamm W, et al (Eds), McGraw Hill, 2008.</li><li><a class="nounderline abstract_t">Haizlip J, Isbey SF, Hamilton HA, et al. Time required for elimination of Neisseria gonorrhoeae from the urogenital tract in men with symptomatic urethritis: comparison of oral and intramuscular single-dose therapy. Sex Transm Dis 1995; 22:145.</a></li><li><a class="nounderline abstract_t">Pathela P, Braunstein SL, Blank S, Schillinger JA. HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry. Clin Infect Dis 2013; 57:1203.</a></li><li><a class="nounderline abstract_t">Cheung KT, Fairley CK, Read TR, et al. HIV Incidence and Predictors of Incident HIV among Men Who Have Sex with Men Attending a Sexual Health Clinic in Melbourne, Australia. PLoS One 2016; 11:e0156160.</a></li><li><a class="nounderline abstract_t">Katz DA, Dombrowski JC, Bell TR, et al. HIV Incidence Among Men Who Have Sex With Men After Diagnosis With Sexually Transmitted Infections. Sex Transm Dis 2016; 43:249.</a></li><li><a class="nounderline abstract_t">Schwarcz S, Weinstock H, Louie B, et al. Characteristics of persons with recently acquired HIV infection: application of the serologic testing algorithm for recent HIV seroconversion in 10 US cities. J Acquir Immune Defic Syndr 2007; 44:112.</a></li><li><a class="nounderline abstract_t">Wind CM, Schim van der Loeff MF, Unemo M, et al. Test of Cure for Anogenital Gonorrhoea Using Modern RNA-Based and DNA-Based Nucleic Acid Amplification Tests: A Prospective Cohort Study. Clin Infect Dis 2016; 62:1348.</a></li><li><a class="nounderline abstract_t">Okah E, Westheimer EF, Jamison K, Schillinger JA. Frequency of Nucleic Acid Amplification Test Positivity Among Men Who Have Sex With Men Returning for a Test-of-Cure Visit 7 to 30 Days After Treatment of Laboratory-Confirmed Neisseria gonorrhoeae Infection at 2 Public Sexual Health Clinics, New York City, 2013 to 2016. Sex Transm Dis 2018; 45:177.</a></li><li><a class="nounderline abstract_t">Bissessor M, Whiley DM, Fairley CK, et al. Persistence of Neisseria gonorrhoeae DNA following treatment for pharyngeal and rectal gonorrhea is influenced by antibiotic susceptibility and reinfection. Clin Infect Dis 2015; 60:557.</a></li><li><a class="nounderline abstract_t">de Vries HJC, de Laat M, Jongen VW, et al. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. Lancet Infect Dis 2022; 22:706.</a></li><li><a class="nounderline abstract_t">Erbelding EJ, Zenilman JM. Toward better control of sexually transmitted diseases. N Engl J Med 2005; 352:720.</a></li><li class="breakAll">http://www.cdc.gov/std/ept/legal/ (Accessed on March 02, 2015).</li><li><a class="nounderline abstract_t">Golden MR. Expedited partner therapy for sexually transmitted diseases. Clin Infect Dis 2005; 41:630.</a></li><li><a class="nounderline abstract_t">Golden MR, Whittington WL, Handsfield HH, et al. Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection. N Engl J Med 2005; 352:676.</a></li><li><a class="nounderline abstract_t">Taylor SN, Morris DH, Avery AK, et al. Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation. Clin Infect Dis 2018; 67:504.</a></li><li><a class="nounderline abstract_t">Taylor SN, Marrazzo J, Batteiger BE, et al. Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. N Engl J Med 2018; 379:1835.</a></li></ol></div><div id="topicVersionRevision">Topic 15892 Version 66.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34292926" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Sexually Transmitted Infections Treatment Guidelines, 2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413622" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17342672" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Update on the management of gonorrhea in adults in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7795109" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Drugs of choice for the treatment of uncomplicated gonococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638719" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Gonorrhea and chlamydia in the United States among persons 14 to 39 years of age, 1999 to 2002.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20470051" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection: how much do we know?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22080266" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Mycoplasma genitalium: should we treat and how?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250178" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250178" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250178" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22250178" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Cephalosporin resistant Neisseria gonorrhoeae: time to consider gentamicin?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17431378" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Update to CDC's sexually transmitted diseases treatment guidelines, 2006: fluoroquinolones no longer recommended for treatment of gonococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4262305" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antibiotic resistance in Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23231489" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460055" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23460055" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Neisseria gonorrhoeae antimicrobial resistance among men who have sex with men and men who have sex exclusively with women: the Gonococcal Isolate Surveillance Project, 2005-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36398578" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33301430" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Notes from the Field: First Case in the United States of Neisseria gonorrhoeae Harboring Emerging Mosaic penA60 Allele, Conferring Reduced Susceptibility to Cefixime and Ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28701272" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sexually transmitted infections: challenges ahead.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27881151" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Gentamicin versus ceftriaxone for the treatment of gonorrhoea (G-TOG trial): study protocol for a randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24492260" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29991383" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2144026" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2144026" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28686231" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antimicrobial resistance in Neisseria gonorrhoeae: Global surveillance and a call for international collaborative action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11709349" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Outbreak of cefozopran (penicillin, oral cephems, and aztreonam)-resistant Neisseria gonorrhoeae in Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17953118" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Threat to cefixime treatment for gonorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19284360" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The use of cephalosporins for gonorrhea: the impending problem of resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25970311" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Gonorrhea Treatment Failures With Oral and Injectable Expanded Spectrum Cephalosporin Monotherapy vs Dual Therapy at 4 Canadian Sexually Transmitted Infection Clinics, 2010-2013.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23299608" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Neisseria gonorrhoeae treatment failure and susceptibility to cefixime in Toronto, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21576437" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21192886" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Ceftriaxone-resistant Neisseria gonorrhoeae, Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22155830" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22155830" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21329645" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Ceftriaxone treatment failure of pharyngeal gonorrhoea verified by international recommendations, Sweden, July 2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23390207" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23390207" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Failure of 500 mg of ceftriaxone to eradicate pharyngeal gonorrhoea, Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20693173" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cephalosporin MIC creep among gonococci: time for a pharmacodynamic rethink?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21734634" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cephalosporin susceptibility among Neisseria gonorrhoeae isolates--United States, 2000-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22421701" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Emergence and characterization of Neisseria gonorrhoeae isolates with decreased susceptibilities to ceftriaxone and cefixime in Canada: 2001-2010.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15729156" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Antimicrobial resistance of Neisseria gonorrhoeae in selected World Health Organization Southeast Asia Region countries: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23001269" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25372111" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A new multidrug-resistant strain of Neisseria gonorrhoeae in Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080084" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Patient-delivered partner treatment for male urethritis: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22316442" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The emerging threat of untreatable gonococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22604449" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22604449" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The ticking time bomb: escalating antibiotic resistance in Neisseria gonorrhoeae is a public health disaster in waiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29045604" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Increases in Neisseria gonorrhoeae With Reduced Susceptibility to Azithromycin Among Men Who Have Sex With Men in Seattle, King County, Washington, 2012-2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22184617" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Neisseria gonorrhoeae with high-level resistance to azithromycin: case report of the first isolate identified in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28549097" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Cluster of Neisseria gonorrhoeae Isolates With High-level Azithromycin Resistance and Decreased Ceftriaxone Susceptibility, Hawaii, 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21844727" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Resistance to azithromycin of Neisseria gonorrhoeae isolates from 2 cities in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25970312" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : High Prevalence of Azithromycin-Resistant Neisseria gonorrhoeae Isolates With a Multidrug Resistance Phenotype in Fukuoka, Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28178112" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Antimicrobial Susceptibility of Neisseria gonorrhoeae in Japan from 2000 to 2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22334602" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Surveillance of gonococcal antimicrobial susceptibility resulting in early detection of emerging resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36001447" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prior Exposure to Azithromycin and Azithromycin Resistance Among Persons Diagnosed With Neisseria gonorrhoeae Infection at a Sexual Health Clinic: 2012-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20940154" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : European surveillance of antimicrobial resistance in Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2955222" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Effect of spectinomycin use on the prevalence of spectinomycin-resistant and of penicillinase-producing Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19901860" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34772893" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Gentamicin Susceptibility in Neisseria gonorrhoeae and Treatment Outcomes for Urogenital Gonorrhea After 25 Years of Sustained Gentamicin Use in Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22492860" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Impact of fluoroquinolone resistance mutations on gonococcal fitness and in vivo selection for compensatory mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22492861" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Fluoroquinolone resistance in Neisseria gonorrhoeae: fitness cost or benefit?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32766725" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Resistance-Guided Treatment of Gonorrhea: A Prospective Clinical Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9652712" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638718" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638718" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17638718" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Antimicrobial resistance for Neisseria gonorrhoeae in the United States, 1988 to 2003: the spread of fluoroquinolone resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985996" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A ROADMAP Plan to Address Research Needs for Gonococcal Antimicrobial Resistance in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29985996" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A ROADMAP Plan to Address Research Needs for Gonococcal Antimicrobial Resistance in China.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33516669" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : The JAID/JSC guidelines to Clinical Management of Infectious Disease 2017 concerning male urethritis and related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22422688" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Efficacy and safety of ceftriaxone for uncomplicated gonorrhoea: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30642924" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pharmacokinetic Data Are Predictive of In Vivo Efficacy for Cefixime and Ceftriaxone against Susceptible and Resistant Neisseria gonorrhoeae Strains in the Gonorrhea Mouse Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7709324" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Treating uncomplicated Neisseria gonorrhoeae infections: is the anatomic site of infection important?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34000039" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Efficacy of 1 g Ceftriaxone Monotherapy Compared to Dual Therapy With Azithromycin or Doxycycline for Treating Extragenital Gonorrhea Among Men Who Have Sex With Men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27332921" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33005903" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Azithromycin susceptibility of Neisseria gonorrhoeae in the USA in 2017: a genomic analysis of surveillance data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28510723" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Decreased Azithromycin Susceptibility of Neisseria gonorrhoeae Isolates in Patients Recently Treated with Azithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1922235" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A comparison of single-dose cefixime with ceftriaxone as treatment for uncomplicated gonorrhea. The Gonorrhea Treatment Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36729626" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Effectiveness of Cefixime for the Treatment of Neisseria gonorrhoeae Infection at 3 Anatomic Sites: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24113412" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Retrospective review of pharyngeal gonorrhea treatment failures in Alberta, Canada.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22874837" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Update to CDC's Sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19546370" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Mosaic penicillin-binding protein 2 in Neisseria gonorrhoeae isolates collected in 2008 in San Francisco, California.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25031289" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31419483" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Gentamicin 240 mg plus azithromycin 2 g vs. ceftriaxone 500 mg plus azithromycin 2 g for treatment of rectal and pharyngeal gonorrhoea: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31056291" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9071422" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea. Azithromycin Gonorrhea Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20940153" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Azithromycin in the treatment of infection with Neisseria gonorrhoeae.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Notice to readers: Discontinuation of spectinomycin</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19911970" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the oropharynx to the urethra among men who have sex with men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21183864" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Chlamydia trachomatis and Neisseria gonorrhoeae transmission from the female oropharynx to the male urethra.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31712813" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Gentamicin Alone Is Inadequate to Eradicate Neisseria Gonorrhoeae From the Pharynx.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19911969" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Pharyngeal gonorrhea: an important reservoir of infection?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23408680" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26293005" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11082757" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : The Waldeyer's ring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19396515" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Mechanism and implication of cephalosporin penetration into oropharyngeal mucosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27998950" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Antiseptic mouthwash against pharyngeal Neisseria gonorrhoeae: a randomised controlled trial and an in vitro study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33676595" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Antiseptic mouthwash for gonorrhoea prevention (OMEGA): a randomised, double-blind, parallel-group, multicentre trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34458921" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Treatment efficacy for rectal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27366021" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Extragenital Infections Caused by Chlamydia trachomatis and Neisseria gonorrhoeae: A Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29028971" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Infrequent Testing of Women for Rectal Chlamydia and Gonorrhea in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34355734" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : The Natural History of Rectal Gonococcal and Chlamydial Infections: The ExGen Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2496606" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2496606" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2496606" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Treatment of gonococcal conjunctivitis with single-dose intramuscular ceftriaxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7652655" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Time required for elimination of Neisseria gonorrhoeae from the urogenital tract in men with symptomatic urethritis: comparison of oral and intramuscular single-dose therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23800942" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : HIV incidence among men with and those without sexually transmitted rectal infections: estimates from matching against an HIV case registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27219005" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : HIV Incidence and Predictors of Incident HIV among Men Who Have Sex with Men Attending a Sexual Health Clinic in Melbourne, Australia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26967302" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : HIV Incidence Among Men Who Have Sex With Men After Diagnosis With Sexually Transmitted Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17075386" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Characteristics of persons with recently acquired HIV infection: application of the serologic testing algorithm for recent HIV seroconversion in 10 US cities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26962074" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Test of Cure for Anogenital Gonorrhoea Using Modern RNA-Based and DNA-Based Nucleic Acid Amplification Tests: A Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29420445" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Frequency of Nucleic Acid Amplification Test Positivity Among Men Who Have Sex With Men Returning for a Test-of-Cure Visit 7 to 30 Days After Treatment of Laboratory-Confirmed Neisseria gonorrhoeae Infection at 2 Public Sexual Health Clinics, New York City, 2013 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25371490" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Persistence of Neisseria gonorrhoeae DNA following treatment for pharyngeal and rectal gonorrhea is influenced by antibiotic susceptibility and reinfection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35065063" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716568" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Toward better control of sexually transmitted diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716568" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Toward better control of sexually transmitted diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080085" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Expedited partner therapy for sexually transmitted diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15716561" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effect of expedited treatment of sex partners on recurrent or persistent gonorrhea or chlamydial infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29617982" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30403954" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
